After the outstanding success of the ColdZyme® Mouth Spray cold treatment in Sweden, Enzymatica has decided to take charge of sales of ColdZyme on the Scandinavian markets itself. For the rest of Europe and other markets, the company will work through licensing and distribution agreements. For these markets, Enzymatica will continue to negotiate with the international pharmaceuticals company, Actavis, but negotiations are also being held with other players.
The successful launch of ColdZyme Mouth Spray in Sweden has propelled ColdZyme into the top 10 best-selling cold treatments by value, with sales exceeding 100,000 units so far this year. On the basis of this highly-encouraging performance, Enzymatica has decided to expand into the Scandinavian market itself, due to the more attractive profitability and the importance of Enzymatica building its own close relationship with customers, markets and the scientific research world on its doorstep. The company has now begun the recruitment process for a Scandinavian Sales Manager and for sales teams for the individual markets.
”Moving into the Scandinavian countries on our own account is the best way for Enzymatica to create value for shareholders and customers, partly through improved margins and also by generating a wider customer contact network on the domestic market. Success in the domestic market is an essential foundation for achieving successful international distribution,” says Michael Edelborg Christensen, CEO of Enzymatica.
Global focus for the negotiations with Actavis
At the end of May, Enzymatica and Actavis issued a Letter of Intent on the sale of ColdZyme Mouth Spray on the Nordic markets. The negotiations with Actavis on ColdZyme Mouth Spray will now focus on the global market.
Distribution agreements for other markets
Enzymatica is working to have distribution and licensing agreements in place for the European and other markets. Enzymatica has recruited additional expertise in business development, and aims to conclude agreements during 2014.
“We have recruited additional expertise in business development for the negotiations to finalise distribution agreements during 2014. Actavis is one of the parties, but we are also in discussions with other distributors. Our aim is to have several markets lined up before the end of next year,” says Michael Edelborg Christensen, CEO of Enzymatica.
For further information on Enzymatica, please contact:
Michael Edelborg Christensen, CEO, Enzymatica AB (publ), +46 (0)768-14 41 66,
About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.